uric acid; SLC2A9; splice variants THE END PRODUCT OF NITROGEN excretion varies among species. Mammals are mainly ureotelic, excreting primarily urea, and for most of them, uric acid is only a metabolic intermediate. Indeed, uric acid is oxidized to the water-soluble allantoin by the urate oxidase (uricase) in the liver and excreted. Humans and great apes, however, have lost uricase activity by mutational silencing. Consequently, humans have relatively high levels of plasma uric acid but the teleological meaning of this evolutionary trait is still elusive. On the one hand, elevated concentrations of uric acid have been proposed to provide neuroprotection through antioxidative effects or to be a useful signaling molecule recognized by the inflammasome (21) . On the other hand, despite this supposedly beneficial role in evolution and due to its limited solubility, high plasma levels of uric acid may be detrimental and have been associated with gout, kidney stones, hypertension, visceral obesity, insulin resistance, diabetes, and cardiovascular and kidney diseases (13, 23) .
Plasma uric acid levels reflect a balance between production and excretion. The liver, the intestine, and the kidneys are the main organs involved in its homeostasis. Production is dependent on organic nutrient intake and endogenous purine recycling, whereas excretion is dependent primarily on renal elimination. In human kidneys, a complex interplay of transporters has been characterized for urate reabsorption, all located along the proximal tubule. A putative four-component model has been proposed (10) , which consists of 1) filtration through the glomerulus, 2) reabsorption, 3) secretion, and 4) postsecretory reabsorption for a final excretion of ϳ5-10% of the filtrated urate. It is noteworthy that the secretory step has been questioned in humans and might play only a minor role (24, 27) . Cloning of several urate transporters has shed some light on the complexity of urate reabsorption, but only URAT1, the human electroneutral urate/anion exchanger expressed in the apical membrane of the proximal tubule, has reconciled a molecular candidate with physiological data and genetics (12) . A voltagedependent basolateral urate extrusion pathway has been described in human kidney vesicles (24) , but its molecular identity has been unveiled only recently (1, 31) .
The solute carrier SLC2A family comprises genes that encode glucose transporters and glucose transporter-like proteins. One family member, SLC2A9 (GLUT9), has been identified as a class II sugar transport facilitator with high sequence similarity to GLUT5 and GLUT11 (2) . Although glucose transport activity has been reported for GLUT9 (2, 7) , it does not seem to be as efficient as for the classic glucose transporter GLUT2. Several recent reports have associated GLUT9 polymorphisms and uric acid levels and have identified GLUT9 as an important genetic determinant of serum uric acid levels (5, 8, 9, 11, 19, 28, 31, 32) .
The mechanisms by which GLUT9 may affect uric acid levels are not precisely known. All recent studies have focused on the characterization of human GLUT9 (1, 8, 31) . Finding an animal model for studying uric acid physiology turned out to be challenging, due to species specificities of uric acid handling and the presence or absence of specific oxidative enzymes (25) . As mice are the most used in vivo genetic models, we performed a detailed characterization of urate transport by mouse GLUT9. Mouse GLUT9 shares 85% homology with human GLUT9 and also has several splice variants. Mouse GLUT9a (GenBank accession no. AF469480) and GLUT9b (GenBank accession no. AY776155) differ at their NH 2 -terminal sequence due to alternative transcription/translation sites. GLUT9b is found in liver and kidneys, whereas GLUT9a is ubiquitous. In the kidney, immunostaining reveals both isoforms of mouse GLUT9 in the basolateral membrane of distal tubules, in contrast to a proximal renal tubular cell staining in humans (2, 18) .
In this study, we examined urate transport properties and kidney distribution of mouse GLUT9 splice variants. In particular, we show that mouse GLUT9-mediated urate transport is electrogenic and voltage dependent and is not influenced by an Na ϩ or Cl Ϫ gradient. Taken together, these data indicate that GLUT9 is probably not a coupled transport system but rather a urate uniporter, similar to most members of the GLUT transporter family, which facilitate glucose transport in an uncoupled mode. We show that, similar to human GLUT9, urate transport by mouse GLUT9 can be inhibited by several uricosuric agents. We also found that phloretin, a specific glucose transporter blocker, inhibits urate transport through GLUT9. Overall, mouse GLUT9 shares transport characteristics close to human GLUT9, but its expression pattern seems to be different, possibly reflecting different urate homeostasis between mice and humans.
MATERIALS AND METHODS
Materials. Cytochalasin B, probenecid, phloretin, losartan, lactate, salicylate, and benzbromarone were purchased from Sigma (St. Louis, MO). Pyrazinoate was from Janssen Chimica (New Brunswick, NJ), and candesartan was from AstraZeneca Pharmaceuticals (Molndal, Sweden). Cloning and cDNAs. Mouse GLUT9a cDNA was amplified from a cDNA library prepared from mouse liver and subcloned into a pBluescript vector using EcoRI and XhoI restriction sites. A COOHterminal FLAG epitope was introduced by PCR using EcoRI and XhoI sites. The final construct was subcloned into a pSDeasy vector. Mouse GLUT9b cDNA was amplified from mouse GLUT9a cDNA by PCR using a sense primer tailed with an EcoRI site and an antisense primer tailed with a StuI restriction site. All constructs have been checked by sequencing.
Expression of GLUT2 and GLUT9 variants in Xenopus laevis oocytes. Stage V-VI oocytes were obtained from X. laevis as described (14) and in accordance with animal regulations of the Veterinarian Office of the Canton de Vaud. Oocytes were injected with 10 ng of mouse GLUT2 (30) or mouse GLUT9a or GLUT9b cRNAs. To check for protein expression, cRNA-injected oocytes were incubated in modified Barth's solution for 48 h and microsomes were prepared as described (14) . Proteins were resolved by SDS-PAGE and transferred overnight to nitrocellulose membranes. Membranes were blocked with 10% nonfat dry milk in Tris-buffered saline containing 0,1% Tween 20 and incubated with anti-mouse GLUT9 antibody (1:500) or GLUT2 antibody (1:500). Specific mGLUT9 antibodies have been raised in rabbits, using a GST fusion peptide containing mouse GLUT9 amino acids 463-522. GLUT2 antibodies have been previously described and characterized (29) . After addition of the secondary anti-rabbit antibody (1:10,000; Amersham Biosciences), the complex was revealed by enhanced chemiluminescence (Amersham Biosciences) according to the manufacturer's protocol.
Urate and glucose uptake in X. laevis oocytes. Transport experiments were carried out after 2 days incubation of GLUT2-or GLUT9 cRNA-injected oocytes and were similar after a 4-day incubation. Glucose uptake was determined in oocytes incubated at room temperature in modified Barth's solution containing 10 Effect of membrane potential on urate uptake. To evaluate the effect of membrane potential on urate transport by GLUT9, we first established experimental conditions in which steady state membrane potentials could be maintained for 20-min periods under conditions similar to the uptake measurements. For this purpose, we used the hyperpolarization produced by activation of the endogenous Na-KATPase in Na ϩ -loaded oocytes when the K ϩ conductances are blocked by barium. Measurements were performed 2 days after cRNA injection. The day before the experiment and to promote the endogenous Na-K-ATPase activity, oocytes were loaded with Na ϩ by exposure to K ϩ -and Ca 2ϩ -free solution (16) . Membrane potentials were measured by an intracellular microelectrode while oocytes were exposed to solutions similar to those used for the uptake experiments [pH 8.3, 100 M urate and (in mM) 75 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 CaCl2, 2 Na-HEPES, and 5 BaCl2 to block K ϩ conductances] followed by a 20-min period in a solution containing 5 mM K ϩ in the absence or presence of 200 M ouabain. As shown in Fig. 3C , activation of Na-K-ATPase by 5 mM K ϩ leads to a steady-state hyperpolarization, which can be completely prevented by the presence of 200 M ouabain.
Urate uptake experiments were then performed under exactly the same experimental conditions except for the presence of 100 M [ 14 C]urate instead of 100 M cold urate and allowed us to compare the urate uptake in hyperpolarized (without ouabain) or depolarized (with ouabain) oocytes.
Electrophysiological current measurements. Oocytes injected with GLUT9 cRNA or water (control) were studied under voltage-clamp condition using a Dagan TEV-200 voltage-clamp apparatus (Dagan, Minneapolis, MN). Measurements were performed at a holding potential of 0 mV in a solution containing (in mM) 100 NaCl, 2.5 KCl, 1 MgCl2, 10 Na-HEPES, and 0.8 CaCl2. The control solution and the urate-containing solution were adjusted to the same pH (7.4 or 8.2, as indicated). The holding potential was 0 mV. Current-voltage (I-V) curves were recorded immediately before and 30 s after addition of 400 M urate. Current and voltage signals were recorded and analyzed by means of a Digidata/Pclamp package from Axon Instruments (Union City, CA).
Tubule microdissection. Tubules were microdissected from male C57/B6 mice that had free access to tap water and standard laboratory chow. After deep anesthesia, kidneys were perfused with 40 g/ml Liberase Blendzyme 2 (Roche Applied Science) dissolved in DMEM/ F-12 (1:1, 21041 medium, Invitrogen). Thin pyramids cut along the corticomedullary axis were further incubated at 37°C for 40 min in the same medium. Microdissection was performed in ice-cold DMEM/ F-12 (1:1) as described (22) . The following structures were isolated: glomeruli; convoluted and straight proximal tubules; medullary and cortical portions of the thick ascending limb; distal convoluted tubules (DCT); connecting tubules (CNT); and cortical and outer medullary portions of the collecting ducts. Tubular length was measured with an ocular micrometer (Zeiss), and pools of 10 -20 microdissected tubules for a total tubular length of ϳ10 mm/pool were transferred to 5 l of DMEM/F-12 (1:1) into 1.5-ml tubes and immediately snap frozen.
RT-PCR. RNA was isolated from each pool of 10-mm microdissected tubules using an RNeasy micro Kit (Qiagen), following the manufacturer's instructions. Elution was done with 12 l of water. Two microliters of RNA were used for single-tube RT-PCR in a total volume of 50 l using a Titan One Tube RT-PCR kit (Roche), following the manufacturer's instructions. Primers were the following: mGLUT9a sense 5Ј-GGGTCACCAGCAGAGGAG-3Ј and antisense 5Ј-TGGACCAAG-GCAGGGACAA-3Ј (ampliconsЈ size 609 bp); mGLUT9b sense 5Ј-AACTCCGCAGAAACCAAGGAAAGC-3Ј and antisense 5Ј-TTCA-AAGAGAAGGTAGCGTGGGCT-3Ј (ampliconsЈ size 675 bp); and mHPRT sense 5Ј-TTATCAGACTGAAGAGCTACTGTAATGATC-3Ј and antisense 5Ј-TTACCAGTGTCAATTATATCTTCAACAATC-3Ј (ampliconsЈ size 126 bp). Reverse transcription was performed at 50°C for 30 min, inactivated for 2 min at 95°C, and immediately followed by 45 cycles (amplification: 94°C, 30 s; 58°C, 30 s; 68°C, 1 min) and by a final elongation step at 68°C for 7 min. The amplicons were loaded on a 2 (mGLUT9a and mGLUT9b) or 3% (mHPRT) agarose gel and had been sequenced.
Statistical analysis. Data were analyzed by using an unpaired t-test to compare two groups of oocytes. Differences between groups were considered significant at P Ͻ 0.05.
RESULTS

Mouse GLUT9 mediates urate, but not glucose transport.
We first studied whether GLUT9 can transport glucose by measuring glucose uptake in X. laevis oocytes. GLUT2, a high-capacity glucose transporter, was used as a positive control. Figure 1A shows a lack of glucose uptake in oocytes expressing GLUT9a compared with a robust cytochalasin Binhibitable glucose uptake measured in oocytes expressing GLUT2. Recent data have shown that human GLUT9, unlike other members of the GLUT family, can transport urate (1, 8, 31) . X. laevis oocytes expressing mouse GLUT9a also exhibited time-dependent transport of urate, which increased linearly during 90 min of incubation (Fig. 1B) , whereas GLUT2-expressing oocytes showed only minimal urate uptake similar to that of water-injected oocytes. After 60-min incubation, urate uptake rate was 15.0 Ϯ 1.3 pmol/h in GLUT9-expressing oocytes compared with 6.5 Ϯ 0.4 pmol/h in water-injected oocytes (P ϭ 0.002). The K m value for urate transport by GLUT9 was determined by measuring the rate of transport over a range of urate concentrations (Fig. 1C) and was found to be 649 Ϯ 18 M. This indicates that mouse GLUT9 has an affinity for urate on the same order of magnitude to what has been described for human GLUT9 (1, 8, 31) and human and mouse URAT1 (12, 17) .
Mouse GLUT9 variants are high-capacity urate transporters differentially expressed in renal tubular segments. In mice (7, 18) as well as in humans (2), several splice variants of GLUT9 Fig. 1 have been described. Mouse GLUT9a and GLUT9b differ in their transcription/translation initiation site, length, and tissue distribution. Interested in mouse renal uric acid transport, we looked for tubular-specific expression of both GLUT9a and GLUT9b splice variants by RT-PCR from microdissected mouse tubules. We found that GLUT9a mRNA is expressed at low abundance in the proximal tubule while GLUT9b mRNA is expressed in the DCT/CNT (Fig. 2A) . We then studied whether the two splice variants have functional differences in transporting uric acid or glucose. Both GLUT9 isoforms were similarly expressed in X. laevis oocytes (Fig. 2B ) and had equivalent transport urate rates (Fig. 2C) . The uptake rate of [ 14 C]urate in oocytes expressing GLUT9 was fourfold higher than that in oocytes expressing GLUT2. Since GLUT9a and GLUT9b have previously been characterized as glucose and fructose transporters (2, 7, 31), we tested whether these sugars were able to compete with urate uptake. Concentrations of glucose or fructose up to 10 mM had no significant effect on the transport of 100 M urate (Fig. 2C) . This suggests that glucose/fructose, if ever transported by GLUT9 isoforms, have different binding sites than urate. Since both isoforms showed similar, high urate transport capacities, we used GLUT9a for further characterization.
Inhibition of urate transport by uricosuric agents. Uricosurics are agents known to promote urate elimination in the urine by modulating renal urate transport. The inhibitory potency of several uricosuric compounds on GLUT9-mediated urate transport was investigated (Table 1) . Benzbromarone, a known inhibitor of URAT1 (12), was the most potent inhibitor. At a concentration of 500 M, benzbromarone reduced urate uptake by 90%. Losartan, an angiotensin II receptor blocker (ARB) known to be uricosuric (6) and mostly used as an antihypertensive agent, inhibited urate uptake by 50% at a concentration of 1 mM. Candesartan, a member of the ARB family, had no significant effect on urate transport at a concentration of 1 mM, confirming that the uricosuric effect of losartan is not class specific. Interestingly, pyrazinoate, the active metabolite of pyrazinamide and a known modulator of urate absorption (26) , exerted only a very slight inhibitory effect on urate uptake via GLUT9. Salicylate and lactate did not induce a significant inhibition of urate transport. Two known GLUT inhibitors, cytochalasin B and phloretin (4), have been probed for their effect on GLUT9. Phloretin, but not cytochalasin B inhibited urate uptake by 50% at a concentration of 1 mM.
Effects of Na ϩ and Cl Ϫ gradients on GLUT9-mediated urate transport. The possibility that GLUT9 would mediate a Na ϩ -or Cl Ϫ -coupled transport, either a cotransport or an exchange type of transport, was tested by measuring urate uptake under conditions in which the transmembrane gradient of Na ϩ or Cl Ϫ was modified. As shown in Fig. 3A , neither decreasing the extracellular concentration of Na ϩ from 89.4 to 4.4 mM, nor decreasing the extracellular concentration of Cl Ϫ from 86.6 to 1.6 mM, had any significant influence on the rate of urate uptake in GLUT9-expressing oocytes. These results speak against a transport of urate by GLUT9 stoichiometrically coupled to a translocation of Na ϩ or Cl Ϫ ions (as it is the case for the URAT1 transport system) (12) .
Voltage dependence of GLUT 9-mediated urate transport. We examined the effect of membrane potential on the uptake of urate under conditions in which the membrane potential was carefully controlled. Using the hyperpolarizing effect of activating Na-K-ATPase under specific experimental conditions (see MATERIALS AND METHODS), we could maintain the membrane potential at stable high negative values (Ϫ98.0 Ϯ 8,3 mV, n ϭ 5) or low values (Ϫ32.0 Ϯ 2,4 mV, n ϭ 5) for relatively long periods of time (see voltage traces in Fig. 3C, for example) . The only difference between these two groups was the presence of acutely added ouabain (which should not have significantly modified the intracellular Na ϩ and K ϩ concentrations in the large intracellular volume during the experimental pe- Fig. 2 . Expression of mouse GLUT9 isoforms and influence of sugars on [ 14 C]urate uptake in X. laevis oocytes. A: RT-PCR from microdissected mouse tubules using specific primers for mGLUT9a and mGLUT9b. The housekeeping gene HPRT is used as a control. ϩ, Positive control, related to amplification from the related plasmid (mGLUT9a or mGLUT9b); -, negative control (no template). Glom, glomerulus; PCT, proximal convoluted tubule; PST, proximal straight tubule; m-and cTAL, medullary and cortical thick ascending limb; DCT, distal convoluted tubule; CNT, connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct. B: Western blotting of mouse GLUT9a and GLUT9b expressed in X. laevis oocytes. C: lack of competition between fructose or glucose and [
14 C]urate uptake in X. laevis oocytes. Oocytes were injected with mGLUT9a, mGLUT9b, or mGLUT2 and subjected to [ 14 C]urate uptake in the presence or absence of fructose or glucose (10 mM). Values are means Ϯ SE of 2 separate experiments, including a total of 28 oocytes issued from 4 different batches. *P Ͻ 0.001 vs. GLUT9a-mediated urate transport without any labeled substrate. $P Ͻ 0.001 vs. GLUT9b-mediated urate transport without any labeled substrate.
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MOUSE GLUT9 TRANSPORT CHARACTERISTICS riod). As shown in Fig. 3B , a large membrane hyperpolarization reduced the GLUT9-specific urate uptake by more than threefold. This result is clearly consistent with the fact that urate is transported into the cell with a net negative charge.
Electrogenic transport of urate by GLUT9. We also examined whether the transport of urate by GLUT9 was electrogenic, i.e., associated with net charge movement. For this purpose, we measured the current induced by urate under voltage-clamp conditions. The measurements were performed in solutions with a pH of 7.4 or 8.2 and the effect of the addition of 400 M urate to the extracellular solution was tested in GLUT9 cRNA-or water-injected oocytes. A major difficulty with these experiments was that addition of 400 M urate induced a large, nonspecific ionic conductance in oocytes expressing GLUT9 or not. This urate-induced conductance was rather variable in different batches of oocytes, appeared with a delay of a few seconds, and was strongly concentration dependent (data not shown). The reversal potential of this nonspecific urate-induced conductance was close to 0 mV (see Fig. 4 , B and C). The GLUT9-specific electrogenic effect of urate had therefore to be studied by subtracting the effect of urate in oocytes expressing GLUT9 from the effects in water-injected oocytes measured in the same oocyte batch. The results of these measurements are shown in Fig. 4 . Figure 4A shows original current traces of the effect of the addition of 400 M urate on a water-injected oocyte (left) and on a GLUT9-expressing oocyte (right), both clamped at a 0-mV potential. In the water-injected oocyte, urate induced a small inward current, while in the GLUT9-expressing oocyte urate induced a very rapid and large outward current. Subtracting the mean urate-induced current in the two oocyte groups shows that GLUT9 was responsible for a large outward current (potentially corresponding to the inflow of anions) at positive membrane potentials (Fig. 4, B and C) . Again, these results are entirely compatible with the fact that urate is translocated into the oocyte by GLUT9 as an uncoupled anion.
These experiments were performed in two solutions with different pH, 7.4 and 8.2. According to urate pK a of 5.75 (15) , the concentrations of uric acid were 8.8 and 1.4 M and those of urate 392 and 398.6 M at pH 7.4 and 8.2, respectively. The fact that urate-induced currents are essentially the same at both pH (compare the I-V curves in Fig. 4 , B and C) strongly suggests that the transported species is urate (whose concentration hardly changes) and not a coupled transport of uric acid (whose concentration is modified Ͼ5-fold) with another anion. These results are again compatible with the fact that urate is the translocated species.
DISCUSSION
GLUT9, a member of the glucose transporter family, also designated as SLC2A9, has been clearly shown to have an important role in the transmembrane transport of urate/uric acid particularly in the liver and in the kidney (1, 8, 18, 31) . Its molecular function, transport mode, and localization have only started to be elucidated, and most published information has been obtained with the human form of GLUT9 (1, 8, 31 ). We present here evidences from flux measurements and electrophysiological experiments performed with mouse GLUT9 expressed in X. laevis oocytes suggesting that, similarly to most other GLUT transporters (3), GLUT9 is a uniport type of transport system. In addition, we have analyzed the two splice variants mGLUT9a and mGLUT9b described in mice and found that they are differentially expressed along the nephron but shared similar transport characteristics in X. laevis oocytes, Comparison with human GLUT9 transport characteristics. As soon as human GLUT9 has been established as a urate transporter, attempts to further characterize its transport modalities have been made. Vitart et al. (31) have shown that human GLUT9 is a high-capacity urate transporter with a K m of ϳ890 M. We indeed show here that mouse GLUT9 reproduces most of the human GLUT9 characteristics. We found a K m of 649 M and a strong voltage dependence of urate transport.
Two types of observations support the assumption that urate is transported with a net negative charge into the cell: first, GLUT9-mediated urate entry into the cell is electrogenic, and second, GLUT9-mediated uptake of urate is voltage dependent. Even if the interpretation of the data is made somewhat difficult by a large, nonspecific (GLUT9-independent) effect of urate on oocyte membrane conductance, our data clearly show that the addition of urate induces a large GLUT9-mediated outward current (inflow of negative charges into the oocyte), a current that becomes larger as the intracellular potential becomes more positive. Our flux measurements, obtained under conditions in which the membrane potential of the oocytes expressing GLUT9 was well controlled, clearly indicate that the transport of urate is voltage dependent in the sense that the inward flux of urate is increased by a positive cell membrane potential. Our measurements of the voltage dependence of GLUT9 urate transport is complementary to that by Anzai et al. (1), who measured the effect of membrane depolarization (even though these authors did not quantify the membrane potential under their experimental conditions), while we measured the effect of membrane hyperpolarization.
Taken together, these observations indicate that urate or uric acid is transported with a net negative charge into the cell. The simplest hypothesis accounting for this observation is that the transported species is the anion urate transported alone. However, any combination of cotransported or exchanged species with a net negative charge could also account for the voltage dependence and the electrogenicity of urate transport.
We have also investigated the possibility that urate or uric acid could be transported in a more complex cotransport or exchange mode with either Na ϩ (as it is the case for the URAT1 transport system) (12) Although it is presently difficult to reconcile all these data, the fact that urate transport is clearly voltage dependent and that the membrane potential was not controlled in most of the flux experiments leaves open the possibility that the reported apparent trans-stimulation observations are secondary to membrane potential changes rather than to a strictly stoichiometrically coupled transport of several molecular species. There is Fig. 4 . Urate transport via mGLUT9 is electrogenic. A: original current recordings, 1 with a water-injected oocyte (left) and 1 with a GLUT9-expressing oocyte (right). The black horizontal bars indicate the time of the addition of 400 M urate. In this example, the holding potential was 0 mV, and the pH was 7.4. In the water-injected oocyte, the addition of urate induced a small inward current that was slowly increasing in amplitude. In the oocytes expressing GLUT9, there was a fast appearance (with a time course as fast as the solution exchange) of a large outward current followed by a slow decline of the current. B and C: current-voltage (I-V) relationship of the current induced by exposure to urate. Results are shown of measurements performed in solutions with a pH of 7.4 (B) and 8.2 (C). I-V curves were recorded immediately before and 30 s after addition of 400 M urate. Values are means Ϯ SE of the difference between the current before and after urate exposure in water-injected (WI; E) or GLUT9-expressing oocytes (Glut9; ‚). F, Difference between the means of WI and GLUT9-expressing oocytes; n ϭ 36 and 48 in each group from 3 different batches of oocytes.
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MOUSE GLUT9 TRANSPORT CHARACTERISTICS also the possibility that GLUT9 mediates a weakly coupled transport system that may function as a uniport as well as a coupled transport system. If GLUT9 functions indeed as a urate uniporter, it would be well suited to mediate the exit step from a cell. Assuming a membrane potential of Ϫ60 mV, a reasonable value for many epithelial cells, GLUT9 would carry out urate extrusion until the concentration of urate would be ϳ10-fold lower in the cell than in the extracellular medium. As suggested by others (1, 8) , GLUT9 could provide the basolateral membrane exit pathway for urate that has entered the epithelial cell through an apical uptake mechanism such as URAT1. However, this new paradigm needs further study to be firmly established, especially in the mouse, where urate handling might be quite different compared to humans.
Whether GLUT9 could transport glucose and/or fructose has been debated lately on the basis of several contradictory reports studying human GLUT9, some relating frank glucose and/or fructose transport (2, 20) , while others having found detectable fructose transport only after several days of incubation (31) or no transport at all (1). We found neither a direct glucose transport via mouse GLUT9 nor a modulation of urate transport by glucose or fructose. Differences between species or in the experimental design could account for the lack of glucose transport and will need further study to solve the issue.
Inhibition by uricosurics. Uric acid reabsorption is under the influence of a large number of pharmacological mediators, and we sought the effect of the major uricosuric agents on mouse GLUT9. We found that benzbromarone, losartan, but not probenecid, salicylate, lactate, candesartan, and pyrazinoate inhibited urate uptake via GLUT9. Anzai et al. (1) found the same pattern when testing human GLUT9, except for probenecide, which inhibited urate uptake by 54%. However, Caulfield et al. (8) did not find any effect of probenecide on human GLUT9-mediated urate uptake. We also tested the glucosetransporter blocker cytochalasin B and phloretin. To our surprise and by contrast to what Caulfield et al. reported, we found an inhibition of urate transport by phloretin. This finding might provide a new therapeutical approach to block uric acid uptake in vivo.
Comparison of localization. Two human GLUT9 splice variants have been localized in the proximal tubule, at the basolateral (GLUT9) and apical sides (GLUT9⌬N), and have been proposed to mediate urate reabsorption (2) . In humans as well as in rats, almost no urate transport has been recorded in the DCT/CNT (25, 33) . We report here the presence of a major urate transporter in the mouse DCT and CNT, as assessed by RT-PCR performed using microdissected tubules and showing that the main splice variant expressed in DCT/CNT is mGLUT9b. These data are compatible with previous descriptions made by Keembiyehetty et al. (18) in immunostained mouse kidney sections in which they found a basolateral staining for GLUT9 in the DCT/CNT. Precise mGLUT9b cellular localization in the DCT/CNT will need further study, and its functional role in mouse urate homeostasis has to be defined in vivo.
In conclusion, we report here the first characterization of the mouse GLUT9 transporter. We found that GLUT9 is a highcapacity and low-affinity urate transporter. GLUT9-mediated urate transport is electrogenic and strongly voltage dependent. Mouse GLUT9 splice variants mGLUT9a and mGLUT9b share the same transport characteristics but were found expressed in different parts of the nephron. This might contribute to species differences in urate handling.
